{
    "clinical_study": {
        "@rank": "104047", 
        "arm_group": {
            "arm_group_label": "BYL719 + AMG 479", 
            "arm_group_type": "Experimental", 
            "description": "For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients will be enrolled sequentially until an MTD or a recommended Phase II dose could be defined. All patients will receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients will receive the same combination treatment."
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part is to\n      estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the\n      combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the\n      clinical efficacy and to further assess the safety of the combination in selected patient\n      populations. Patients will be treated until progression of disease, unacceptable toxicity\n      develops, or withdrawal of informed consent, whichever occurs first. All patients will be\n      followed up.  At a minimum, patients must complete the safety follow-up assessments 30 days\n      after the last dose of the study treatment."
        }, 
        "brief_title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "PIK3CA Mutated Advanced Solid Tumors,", 
            "PIK3CA Amplified Advanced Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part is to\n      estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the\n      combination of BYL719 and AMG 479 (ganitumab), followed by the phase II part to assess the\n      clinical efficacy and to further assess the safety of the combination in selected patient\n      populations. The dose escalation part of the study will be guided by a Bayesian Logistic\n      Regression Model (BLRM).\n\n      Once MTD/RP2D has been determined, patients will be enrolled in two Phase II arms. Patients\n      with PIK3CA mutated or amplified hormone receptor positive breast carcinoma will be enrolled\n      in Arm 1; patients with PIK3CA mutated or amplified ovarian carcinoma will be enrolled in\n      Arm 2. Patients will be treated until progression of disease, unacceptable toxicity\n      develops, or withdrawal of informed consent, whichever occurs first. All patients will be\n      followed up.  At a minimum, patients must complete the safety follow-up assessments 30 days\n      after the last dose of the study treatment. In addition, patients who have not progressed at\n      the time of discontinuation of study treatment should have radiological follow-up for the\n      disease status and phase II patients will be followed for survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Written informed consent.\n\n          -  Patients aged \u2265 18 years (male or female).\n\n          -  Patients with the following histologically/cytologically-confirmed advanced solid\n             tumors with documented somatic PIK3CA mutations or amplifications in tumor tissue:\n\n          -  Hormone receptor positive breast carcinoma\n\n          -  Ovarian carcinoma\n\n          -  Other tumors upon agreement with sponsor\n\n          -  Adequate organ function\n\n          -  Negative serum pregnancy test\n\n        Exclusion criteria:\n\n          -  Patients with known history of severe infusion reactions to monoclonal antibodies.\n\n          -  Patients with primary CNS tumor or CNS tumor involvement.\n\n          -  History of thromboembolic event requiring full-dose anti-coagulation therapy any time\n             prior to enrollment.\n\n          -  Clinically significant cardiac disease.\n\n          -  History of another malignancy within last 2 years.\n\n          -  Pregnant or nursing (lactating) women.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708161", 
            "org_study_id": "CBYL719X2105J", 
            "secondary_id": "2012-001962-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "BYL719 + AMG 479", 
                "description": "BYL719 is a small molecule inhibiting PI3-Kinase.", 
                "intervention_name": "BYL719", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BYL719 + AMG 479", 
                "description": "AMG 479 is a monoclonal antibody directed against IGF1-R.", 
                "intervention_name": "AMG 479", 
                "intervention_type": "Drug", 
                "other_name": "ganitumab"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "PIK3CA mutation, advanced solid tumor, breast cancer, ovarian cancer", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vancampbell@mednet.ucla.edu", 
                    "last_name": "Vanity Campbell", 
                    "phone": "310-586-2094"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles TORI"
                }, 
                "investigator": {
                    "last_name": "Zev A. Wainberg", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brattner@partners.org", 
                    "last_name": "Barbara S. Rattner", 
                    "phone": "617-724-0865"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Mass General 2"
                }, 
                "investigator": {
                    "last_name": "Jose Baselga", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "loughlib@mskcc.org", 
                    "last_name": "Bernadette Loughlin", 
                    "phone": "646-888-4165"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center MSKCC 5"
                }, 
                "investigator": {
                    "last_name": "Gary K. Schwartz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alange@acornresearch.net", 
                    "last_name": "Amy Lange", 
                    "phone": "+1 901 683 0055 1049"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "The West Clinic Dept. of Onc."
                }, 
                "investigator": {
                    "last_name": "Daruka Mahadevan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Davis0043@mc.duke.edu", 
                    "last_name": "Patricia Davis", 
                    "phone": "615-329-7240"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute SCRI 3"
                }, 
                "investigator": {
                    "last_name": "Jeffrey R. Infante", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "41013"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28033"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Spain: Spanish Agency for Medicines and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase lb only", 
                "measure": "Incidence of dose limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "Cycle 1 (initial 28 days of treatment)"
            }, 
            {
                "description": "Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 8 weeks during the 6 months immediately following start of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "As per RECIST 1.1 (phase lb & ll)", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 8 weeks during the 6 months immediately following start of treatment"
            }, 
            {
                "description": "As per RECIST 1.1 (Phase lb & ll)", 
                "measure": "Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 8 weeks during the 6 months immediately following start of treatment"
            }, 
            {
                "description": "As per RECIST 1.1 (phae lb & ll)", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 8 weeks during the 6 months immediately following start of treatment"
            }, 
            {
                "description": "Phase ll only", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Every 8 weeks during the 6 months immediately following start of treatment; 4-monthly thereafter for discontinued patients"
            }, 
            {
                "description": "phase lb & ll", 
                "measure": "Number of patients with Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, up to 30 weeks"
            }, 
            {
                "description": "phase lb & ll", 
                "measure": "Number of patients with Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to 30 weeks"
            }, 
            {
                "description": "phase lb & ll", 
                "measure": "Change in hematology and chemistry values", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, up to 30 weeks"
            }, 
            {
                "description": "phase lb & ll", 
                "measure": "Change in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, up to 30 weeks"
            }, 
            {
                "description": "phase lb & ll", 
                "measure": "Change in electrocardiograms (ECGs)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, up to 30 weeks"
            }, 
            {
                "description": "Plasma concentration for BYL719; Serum concentration for AMG 479 (ganitumab); cycle 1 = initial 28 days of treatment", 
                "measure": "Plasma/serum concentration versus time profiles", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 1, Cycle 1 Day 15"
            }, 
            {
                "description": "Standard non-compartmental PK parameters e.g. AUC, Cmax, apparent terminal elimination half-life; cycle 1 = initial 28 days of treatment", 
                "measure": "Derived basic pharmacokinetics paramaeters of BYL719 and AMG479", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 1, Cycle 1 Day 15"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}